子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移 | CN201080040990.1 | 2010-08-09 | CN102510719B | 2015-07-22 | I·J·菲德勒; S-J·金 |
| 本公开内容涉及用于与细胞毒性化学治疗剂、放射疗法或两者组合在脑转移的预防或治疗中使用的内皮素受体拮抗剂。内皮素受体拮抗剂可以是例如波生坦、马西替坦或波生坦和马西替坦的混合物。 | ||||||
| 2 | 由源于虹彩组织的神经干细胞生产网膜神经细胞的方法、以及由该方法得到的网膜神经细胞 | CN200480014244.X | 2004-06-11 | CN1795266B | 2010-08-18 | 小阪美津子 |
| 本发明提供一种网膜神经细胞的生产方法以及由该生产方法得到的网膜神经细胞。本发明的网膜神经细胞的生产方法为，由虹彩色素上皮细胞诱导分化网膜神经细胞，从而来生产网膜神经细胞。其第1种方法为，对源于哺乳类的虹彩色素上皮细胞和源于鸟类的胚胎网膜干细胞实施共同培养。其第2种方法为，在分离了鸟类或哺乳类等的虹彩色素上皮细胞后，对该虹彩色素上皮细胞实施接触培养。根据上述方法，能够利用从患者自身采集的虹彩色素上皮细胞来生产网膜神经细胞，所以，可实现非常有效的再生治疗。 | ||||||
| 3 | 由源于虹彩组织的神经干细胞生产网膜神经细胞的方法、以及由该方法得到的网膜神经细胞 | CN200480014244.X | 2004-06-11 | CN1795266A | 2006-06-28 | 小阪美津子 |
| 本发明提供一种网膜神经细胞的生产方法以及由该生产方法得到的网膜神经细胞。本发明的网膜神经细胞的生产方法为，由虹彩色素上皮细胞诱导分化网膜神经细胞，从而来生产网膜神经细胞。其第1种方法为，对源于哺乳类的虹彩色素上皮细胞和源于鸟类的胚胎网膜干细胞实施共同培养。其第2种方法为，在分离了鸟类或哺乳类等的虹彩色素上皮细胞后，对该虹彩色素上皮细胞实施接触培养。根据上述方法，能够利用从患者自身采集的虹彩色素上皮细胞来生产网膜神经细胞，所以，可实现非常有效的再生治疗。 | ||||||
| 4 | 一种治疗脊髓损伤的方法和治疗剂 | CN02816437.7 | 2002-08-23 | CN1545416A | 2004-11-10 | 川口三郎; 西尾健资 |
| 一种用于治疗脊髓损伤的治疗剂，所述治疗剂包含作为活性成分的神经胶质细胞，所述神经胶质细胞包括作为CNS胶质细胞的I型星形胶质细胞的祖细胞和II型星形胶质细胞的祖细胞和04祖细胞；和一种特征在于通过将有效剂量的上述治疗剂局部给药而治疗脊髓损伤的方法。 | ||||||
| 5 | 一种人源脂肪干细胞来源的神经元细胞的制备方法及其应用 | CN201610142883.9 | 2016-03-14 | CN105567636A | 2016-05-11 | 曹晖; 孙振华 |
| 本发明的人源脂肪干细胞来源的神经元细胞的制备方法，包括以下步骤：将人源脂肪干细胞体外分离、培养、鉴定；将得到的所述人源脂肪干细胞，采用SHH和RA共同诱导分化为运动神经元细胞；将得到的所述运动神经元细胞体外培养，使其成长为成熟的具有电生理功能的功能性运动神经元细胞。本发明的制备方法，实现了简单易行、分化得率高的神经元细胞的制备，提高了脂肪干细胞向运动神经元定向分化的转分化效率和特异性。 | ||||||
| 6 | 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移 | CN201080040990.1 | 2010-08-09 | CN102510719A | 2012-06-20 | I·J·菲德勒; S-J·金 |
| 本发明内容涉及用于与细胞毒性化学治疗剂、放射疗法或两者组合在脑转移的预防或治疗中使用的内皮素受体拮抗剂。内皮素受体拮抗剂可以是例如波生坦、马西替坦或波生坦和马西替坦的混合物。 | ||||||
| 7 | 脑信号蛋白6A促进髓鞘形成和少突胶质细胞分化的用途 | CN200880003680.5 | 2008-02-04 | CN101631559A | 2010-01-20 | 阿莱恩·舍多塔尔; 沙·米; 弗雷德里克·伯纳德 |
| 本发明提供了通过施用Sema6A多肽而治疗涉及脱髓鞘和髓鞘形成障碍的疾病、病症或损伤(包括多发性硬化)的方法。 | ||||||
| 8 | 脉络丛制品及其用途 | CN200680012956.7 | 2006-04-18 | CN101189328A | 2008-05-28 | R·B·埃利奥特; S·J·M·斯金纳; L·D·C·E·奥雷利亚纳; C·萨诺斯 |
| 本发明涉及脉络丛细胞和/或脉络丛条件培养基用于增加非脉络丛细胞在长期或短期培养中生长、存活和/或保持其功能的用途。 | ||||||
| 9 | 一种治疗脊髓损伤的治疗剂 | CN02816437.7 | 2002-08-23 | CN1270727C | 2006-08-23 | 川口三郎; 西尾健资 |
| 一种用于治疗脊髓损伤的治疗剂，所述治疗剂包含作为活性成分的神经胶质细胞，所述神经胶质细胞包括作为CNS胶质细胞的I型星形胶质细胞的祖细胞和Ⅱ型星形胶质细胞的祖细胞和O4祖细胞；和一种特征在于通过将有效剂量的上述治疗剂局部给药而治疗脊髓损伤的方法。 | ||||||
| 10 | 从干细胞生成神经细胞的方法、神经细胞及其应用 | CN201080005013.8 | 2010-07-22 | CN102741398B | 2014-06-25 | 杨银学; 魏军; 李玉奎; 王立斌; 马立君; 刘婷; 马晓娜; 范恒; 朱永朝; 叶萍; 金毅然 |
| 本发明属于细胞移植领域。具体而言，本发明提供了采用干细胞生成可用于治疗神经功能丧失性伤病的神经细胞的方法，其中所述干细胞为人体来源的间质干细胞，优选来自人体的胎盘间质干细胞、骨髓间质干细胞、脂肪间质干细胞和肝脏间质干细胞。本发明还提供了所述方法和所生成的神经细胞在制备治疗神经功能丧失性伤病的药物中的用途，以及治疗神经功能丧失性伤病中的用途。本发明进一步提供了治疗神经功能丧失性伤病的方法。 | ||||||
| 11 | 一种由源于虹彩组织的神经干细胞生产网膜神经细胞的方法 | CN200710196506.4 | 2004-06-11 | CN101186900B | 2010-09-15 | 小阪美津子 |
| 本发明提供一种网膜神经细胞的生产方法以及由该生产方法得到的网膜神经细胞。本发明的网膜神经细胞的生产方法为，由虹彩色素上皮细胞诱导分化网膜神经细胞，从而来生产网膜神经细胞。其第1种方法为，对源于哺乳类的虹彩色素上皮细胞和源于鸟类的胚胎网膜干细胞实施共同培养。其第2种方法为，在分离了鸟类或哺乳类等的虹彩色素上皮细胞后，对该虹彩色素上皮细胞实施接触培养。根据上述方法，能够利用从患者自身采集的虹彩色素上皮细胞来生产网膜神经细胞，所以，可实现非常有效的再生治疗。 | ||||||
| 12 | 一种生产网膜神经细胞的方法、以及所得到的网膜神经细胞 | CN200710196506.4 | 2004-06-11 | CN101186900A | 2008-05-28 | 小阪美津子 |
| 本发明提供一种网膜神经细胞的生产方法以及由该生产方法得到的网膜神经细胞。本发明的网膜神经细胞的生产方法为，由虹彩色素上皮细胞诱导分化网膜神经细胞，从而来生产网膜神经细胞。其第1种方法为，对源于哺乳类的虹彩色素上皮细胞和源于鸟类的胚胎网膜干细胞实施共同培养。其第2种方法为，在分离了鸟类或哺乳类等的虹彩色素上皮细胞后，对该虹彩色素上皮细胞实施接触培养。根据上述方法，能够利用从患者自身采集的虹彩色素上皮细胞来生产网膜神经细胞，所以，可实现非常有效的再生治疗。 | ||||||
| 13 | 制备星形胶质细胞样细胞的条件培养基的方法 | CN200580037862.0 | 2005-09-05 | CN101052711A | 2007-10-10 | 中山孝; 井上顺雄; 近藤靖; 铃木丰; 奥野刚 |
| 公开了制备来源于胚胎干细胞的星形胶质细胞样细胞的条件培养基的方法，其特征在于培养通过胚胎干细胞分化所制备的星形胶质细胞样细胞；由所述方法获得的培养基，该条件培养基用于培养神经细胞以及用于诱导胚胎干细胞分化为神经细胞的用途。 | ||||||
| 14 | 体外诱导多巴胺能的细胞 | CN95196843.2 | 1995-11-14 | CN1170434A | 1998-01-14 | 塞缪尔·韦斯; 布伦特·A·雷诺兹 |
| 神经细胞中酪氨酸羟化酶的体外表达可通过将神经细胞与一种培养基接触进行诱导,该培养基至少含有成纤维细胞生长因子族中一员,并配合条件培养基或转化生长因子β族的分子。本方法诱导从正常情况下非多巴胺能的神经组织,如纹状体和皮层中所得的神经细胞,使之表达酪氨酸羟化酶。这些细胞可用于治疗需要多巴胺能的细胞的患者的神经障碍。 | ||||||
| 15 | Method for transplanting cells into the brain and therapeutic uses therefor | US460706 | 1995-06-02 | US6060048A | 2000-05-09 | Bruce D. Cherksey |
| A method for grafting a cell in the brain of a mammalian subject is accomplished by attaching the cell to a support matrix so that the cell attaches to the matrix surface, and implanting the support matrix with the attached cell into the brain. Preferred support matrices are glass or plastic microbeads, either solid or porous, having a diameter from about 90 to about 125 .mu.m. The method employs cells of different types, preferably cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury. | ||||||
| 16 | Method for increasing the viability of cells which are administered to the brain or spinal cord | US91629 | 1993-07-13 | US5618531A | 1997-04-08 | Bruce D. Cherksey |
| A method for increasing the viability of viable cells which are administered to the brain or spinal cord of a mammalian subject. This method is accomplished by attaching the cell to a support matrix so that the cell attaches to the matrix surface, and implanting the support matrix with the attached cell into the brain or spinal cord. Preferred support matrices are glass or plastic microbeads, either solid or porous, having a diameter from about 90 to about 125 .mu.m. The method employs cells of different types, preferably cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury. | ||||||
| 17 | Temporary living skin replacement | US200140 | 1994-02-18 | US5460939A | 1995-10-24 | John F. Hansbrough; Gail K. Naughton |
| The present invention relates to a living skin replacement. In particular, it relates to a biosynthetic dressing material composed of a living stromal tissue prepared from stromal cells such as fibroblasts cultured upon a three-dimensional framework and a transitional covering which acts as an epidermal replacement. Such a living skin replacement provides long-term biologic coverage of full-thickness wound defects. Since human fibroblasts are known to be relatively non-antigenic when transferred to allogeneic hosts, a temporary living skin replacement made up of such cells attached to a transitional covering may replace the use of cadaveric skin allografts for achieving temporary wound closure in cases where the patients lack enough healthy skin for autografts. | ||||||
| 18 | Method for production of neuroblasts | US95769 | 1998-06-10 | US6045807A | 2000-04-04 | Fred H. Gage; Jasodhara Ray |
| A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts. | ||||||
| 19 | In vitro induction of dopaminergic cells | US482079 | 1995-06-07 | US5981165A | 1999-11-09 | Samuel Weiss; Brent Reynolds |
| A culture method for inducing the expression of tyrosine hydroxylase in neural cells is provided. Mammalian CNS neural cells are cultured in the presence of a fibroblast growth factor and at least one selected from a member of the transforming growth factor beta family, a feeder layer bed of cells, and cell conditioned medium. Cells cultured as provided above may be transplanted to provide dopaminergic cells to a patient. The cells may also be used in methods for drug screening. | ||||||
| 20 | Method for transplanting cells into the brain and therapeutic uses therefor | US460700 | 1995-06-02 | US5750103A | 1998-05-12 | Bruce D. Cherksey |
| A method for grafting a cell in the brain of a mammalian subject is accomplished by attaching the cell to a support matrix so that the cell attaches to the matrix surface, and implanting the support matrix with the attached cell into the brain. A syringe containing viable cells that are attached to a matrix surface may be used to transplant the cells into the brain or spinal cord of a mammalian subject. Preferred support matrices are glass or plastic microbeads, either solid or porous, having a diameter from about 90 to about 125 .mu.m. The method employs cells of different types, preferably cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury. | ||||||
QQ群二维码
意见反馈
意见反馈